Allogene Therapeutics, Inc.(ALLO)

$2.07—

Chart

Allogene Therapeutics, Inc.(ALLO)

NASDAQ

$2.07—

Chart Studio

ALLO(ALLO)

ALLO

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.17

Nov 5, 2026 · Reports after close

Revenue Estimate

$2,500

FY2030E EPS$0.91

Analyst Sentiment

Wall St. Consensus

Buy

30 analysts·High coverage

Score

19 Buy (63%)10 Hold (33%)1 Sell (4%)

Rating Breakdown

Strong Buy

00%

Buy

1963%

Hold

1033%

Sell

13%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$3.85

+86.0%

Consensus

$6.42

+210.4%

Bull

$9.00

+334.8%

12-Month Target Range30 analysts

$3.85$6.42$9.00

Current $2.07Consensus

Current Price

$2.07

Upside to Consensus

$4.36

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+193663.33%

EPS—

FY2028

Rev+618.88%

EPS—

FY2029

Rev+317.36%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$6,000	$12M	$84M	$349M	$665M
Low	$6,000	$12M	$84M	$349M	$665M
High	$6,000	$12M	$84M	$349M	$665M
EBITDA Avg	$-3,600	$-7M	$-50M	$-209M	$-399M
Low	$-3,600	$-7M	$-50M	$-209M	$-399M
High	$-3,600	$-7M	$-50M	$-209M	$-399M
EBIT Avg	$-3,600	$-7M	$-50M	$-209M	$-399M
Low	$-3,600	$-7M	$-50M	$-209M	$-399M
High	$-3,600	$-7M	$-50M	$-209M	$-399M
Net Income Avg	$-168M	$-152M	$-169M	$-13M	$200M
Low	$-192M	$-204M	$-240M	$-13M	$200M
High	$-136M	$-100M	$-64M	$-13M	$200M
EPS Avg	$-0.72	$-0.76	$-0.71	$-0.06	$0.91
Low	$-0.87	$-0.93	$-1.09	$-0.06	$0.91
High	$-0.61	$-0.45	$-0.29	$-0.06	$0.91
Analysts (Rev / EPS)	6 / 7	5 / 6	7 / 9	3 / 3	5 / 3

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$2,500	$2,500	$5,000	$6,667	$6,667	$6,667
Low	$2,500	$2,500	$5,000	$6,667	$6,667	$6,667
High	$2,500	$2,500	$5,000	$6,667	$6,667	$6,667
EBITDA Avg	$-1,500	$-1,500	$-3,000	$-4,000	$-4,000	$-4,000
Low	$-1,500	$-1,500	$-3,000	$-4,000	$-4,000	$-4,000
High	$-1,500	$-1,500	$-3,000	$-4,000	$-4,000	$-4,000
EBIT Avg	$-1,500	$-1,500	$-3,000	$-4,000	$-4,000	$-4,000
Low	$-1,500	$-1,500	$-3,000	$-4,000	$-4,000	$-4,000
High	$-1,500	$-1,500	$-3,000	$-4,000	$-4,000	$-4,000
Net Income Avg	$-42M	$-45M	$-45M	$-47M	$-47M	$-55M
Low	$-52M	$-45M	$-45M	$-47M	$-47M	$-55M
High	$-35M	$-45M	$-45M	$-47M	$-47M	$-55M
EPS Avg	$-0.18	$-0.19	$-0.19	$-0.20	$-0.20	$-0.23
Low	$-0.22	$-0.19	$-0.19	$-0.20	$-0.20	$-0.23
High	$-0.14	$-0.19	$-0.19	$-0.20	$-0.20	$-0.23
Analysts (Rev / EPS)	9 / 5	7 / 1	8 / 1	4 / 3	4 / 3	8 / 1

Earnings Surprises

Recent Analyst Actions

Apr 14, 2026Bernstein

Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein

Target:$3.85

+25.8%from $3.06

Apr 14, 2026Robert W. Baird

Allogene Therapeutics price target raised to $9 from $7 at Baird

Target:$9.00

+194.1%from $3.06

May 16, 2024H.C. Wainwright

Allogene (ALLO) PT Lowered to $9 at H.C. Wainwright

Target:$9.00

+202.0%from $2.98

May 14, 2024B.Riley Financial

Allogene (ALLO) PT Lowered to $7 at B.Riley

Target:$7.00

+141.4%from $2.90

Jun 13, 2022Robert W. Baird

Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird

Target:$11.00

+12.9%from $9.74

Jan 3, 2022Guggenheim

Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim

Target:$35.00

+128.9%from $15.29

Dec 3, 2021Canaccord Genuity

Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord

Target:$55.00

+212.1%from $17.62

Oct 8, 2021Roth Capital

Allogene Therapeutics price target lowered to $35 from $60 at Roth Capital

Target:$35.00

+166.6%from $13.13

Oct 8, 2021Bank of America Securities

Allogene (ALLO) PT Lowered to $32 at BofA Securities

Target:$32.00

+143.7%from $13.13

Oct 8, 2021Oppenheimer

Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer

Target:$40.00

+204.6%from $13.13

Oct 8, 2021Jefferies

Allogene (ALLO) PT Lowered to $30 at Jefferies

Target:$30.00

+128.5%from $13.13

Sep 23, 2021Raymond James

Allogene Therapeutics upgraded to Outperform from Market Perform at Raymond James

Target:$36.00

+30.2%from $27.64

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance